PARP1 and cancer: EZH2 inhibitors reduces proliferation of BAP1-mutant mesothelioma cell lines, while platinum-based drugs and PARP-1 inhibitors should be able to target cancer cells with defective DNA repair mechanisms [9, 44, 48].